ReportPsoriasis is associated with lipid abnormalities at the onset of skin disease
Section snippets
Cases
The recruitment process has been described.18 In brief, the cases comprised consecutive patients older than 15 years of age with onset of psoriasis lesions on nonhairy skin within the past 12 months before consultation. A total of 200 patients living in the county of Stockholm were enrolled. All patients were examined by one dermatologist (L. M.) at the Department of Dermatology, Karolinska University Hospital, Stockholm, Sweden between 2001 and 2002. Measurement of skin disease severity was
Results
Demographic data were similar for patients and control subjects except for smoking, where patients with psoriasis more often were current or previous cigarette smokers than control subjects (Table I). There was no difference between patients and control subjects with regard to body mass index (BMI), systolic and diastolic blood pressure, physical activity, and alcohol consumption.
Discussion
Almost half a century ago, Lea, Cornish, and Block21 reported increased serum lipid concentrations in patients with psoriasis. Since then, much research has been performed in this area, most of which consistently points to a raised prevalence of lipid abnormalities in individuals diagnosed with psoriasis. However, to date all accumulated knowledge derives from studying psoriasis patients without considering disease duration. To our knowledge, the present study provides the first evaluation of
References (35)
- et al.
Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis
Clin Chim Acta
(2003) - et al.
Dyslipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease
Clin Chim Acta
(2001) - et al.
Disease concomitance in psoriasis
J Am Acad Dermatol
(1995) - et al.
Elevation of fasting serum lipids in patients treated with low-dose cyclosporine for severe plaque-type psoriasis. An assessment of clinical significance when viewed as a risk factor for cardiovascular disease
J Am Acad Dermatol
(1992) - et al.
Psoriasis phenotype at disease onset: clinical characterization of 400 adult cases
J Invest Dermatol
(2005) - et al.
Studies on serum lipids, proteins, and lipoproteins in psoriasis
J Invest Dermatol
(1958) - et al.
Alterations of VLDL composition during alimentary lipemia
J Lipid Res
(1997) Hypertriglyceridaemia, triglyceride-rich lipoproteins and coronary heart disease
Baillieres Clin Endocrinol Metab
(1990)- et al.
Plasma lipoproteins mediate platelet adhesion
Biochem Biophys Res Commun
(1990) - et al.
A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids
J Lipid Res
(2001)
Dominant lesional T cell receptor rearrangements persist in relapsing psoriasis but are absent from nonlesional skin: evidence for a stable antigen-specific pathogenic T cell response in psoriasis vulgaris
J Invest Dermatol
T cells involved in psoriasis vulgaris belong to the Th1 subset
J Invest Dermatol
Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines
Atherosclerosis
Psoriasis—epidemiology and clinical spectrum
Clin Exp Dermatol
Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients
Eur J Epidemiol
The variation of serum lipoprotein (a) level with disease activity in psoriasis
Br J Dermatol
Serum lipoproteins in middle-aged men with psoriasis
Acta Derm Venereol
Cited by (289)
Modulation of oxidative stress in psoriasis: Pathophysiology and therapy
2023, Modulation of Oxidative Stress: Biochemical, Physiological and Pharmacological AspectsNew Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies
2021, Journal of Investigative DermatologyCitation Excerpt :In a recent study, liraglutide reduced psoriasiform inflammation in mice that were obese and had diabetes, with improvements in PASI, insulin resistance, and glucose metabolism positively correlating with IL-23, IL-17, IL-22, and TNF-α levels (Chen et al., 2020). In addition to metabolic dysfunction, patients with PsV and PsA have a higher prevalence of CV risk factors such as dyslipidemia (Dreiher et al., 2008; Holzer et al., 2012; Ma et al., 2014; Mallbris et al., 2006), lipoprotein dysfunction (Ahlehoff et al., 2011; Cerman et al., 2008; Hjuler et al., 2017; Mehta et al., 2013, 2012; Rivers et al., 2018; Sorokin et al., 2018), and adiposity (Sajja et al., 2018; Snekvik et al., 2017) and are at increased risk for CV events, including myocardial infarction (MI), stroke, and CV death (Ahlehoff et al., 2011; Brauchli et al., 2009; Gelfand et al., 2011, 2010, 2007, 2006; Hu and Lan, 2017; Kimball et al., 2010; Kurd and Gelfand, 2009; Mehta et al., 2013, 2011a, 2010; Neimann et al., 2006; Noe et al., 2018; Ogdie et al., 2015). Furthermore, psoriasis is associated with a greater presence and extent of vascular inflammation as assessed by 18F-fluorodeoxyglucose positron emission tomography with computed tomography (CT) (Dey et al., 2017; Mehta et al., 2011b; Naik et al., 2015; Youn et al., 2015), lipid-rich noncalcified coronary disease, coronary artery calcium as assessed by CT (Elnabawi et al., 2019, Joshi et al., 2018, Lerman et al., 2017, Mansouri et al., 2016, Staniak et al., 2014), and carotid as well as femoral atherosclerotic plaques as assessed by ultrasound (Di Minno et al., 2011; Eder et al., 2018, 2013).
Comorbidities in Early Psoriatic Arthritis: Data From the Metabolic Disturbances in Psoriatic Arthritis Cohort Study
2024, Arthritis Care and ResearchCHARACTERISTICS OF CARDIOVASCULAR RISK IN PATIENTS WITH PSORIATIC ARTHRITIS
2024, Vestnik Sovremennoi Klinicheskoi MedicinyA Bibliometric Analysis of Global Research Trends in Psoriasis and Metabolic Syndrome
2024, Clinical, Cosmetic and Investigational Dermatology
Funding sources: Supported by funds from Swedish Heart-Lung Foundation, Swedish Psoriasis Association, Swedish Medical Research Council, Welander-Finsen Foundation, and Karolinska Institutet.
Conflicts of interest: None identified.